1.
Eur J Gastroenterol Hepatol
; 34(4): 372-374, 2022 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34034281
RESUMO
There is a paucity of treatment options for patients who have failed multiple biologics. A drawback of biologic therapies is their selectivity in targeting a single pathway. We report the use of dual biologic therapy with vedolizumab and ustekinumab for three highly refractory patients who previously failed both of these medications as monotherapy. The dual biologic therapy led to the closure of a recto-vaginal fistula and restoration of continuity after takedown of a stoma.